Oryzon Genomics S.A. (ORY.MC)
EUR 2.9
(2.47%)
EUR 2.9
(2.47%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 13.94 Million EUR | 84.71% |
| 2022 | 15.23 Million EUR | 54.36% |
| 2021 | 9.86 Million EUR | 9.73% |
| 2020 | 8.99 Million EUR | 0.0% |
| 2019 | - EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 3.93 Million EUR | 0.0% |
| 2024 Q3 | - EUR | -100.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 Q4 | 3.18 Million EUR | -6.66% |
| 2023 FY | 13.94 Million EUR | -8.44% |
| 2023 Q3 | 3.41 Million EUR | -6.76% |
| 2023 Q2 | 3.65 Million EUR | -1.06% |
| 2023 Q1 | 3.69 Million EUR | 0.0% |
| 2022 Q4 | - EUR | 0.0% |
| 2022 FY | 15.23 Million EUR | 54.36% |
| 2021 FY | 9.86 Million EUR | 9.73% |
| 2020 FY | 8.99 Million EUR | 0.0% |
| 2019 FY | - EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| ABIONYX Pharma SA | 618 Thousand EUR | -2156.944% |
| ABIVAX Société Anonyme | 3.91 Million EUR | -256.36% |
| Adocia SA | 1.38 Million EUR | -907.07% |
| Aelis Farma SA | 12.35 Million EUR | -12.865% |
| Biophytis S.A. | -803 Thousand EUR | 1836.976% |
| Advicenne S.A. | 1.42 Million EUR | -878.115% |
| genOway Société anonyme | 20.1 Million EUR | 30.609% |
| IntegraGen SA | 5.01 Million EUR | -177.942% |
| Medesis Pharma S.A. | -2.66 Million EUR | 623.419% |
| Neovacs S.A. | 29.31 Thousand EUR | -47481.067% |
| NFL Biosciences SA | -56.06 Thousand EUR | 24978.557% |
| Plant Advanced Technologies SA | 2.15 Million EUR | -547.861% |
| Quantum Genomics Société Anonyme | -1.41 Million EUR | 1082.74% |
| Sensorion SA | 3.78 Million EUR | -268.227% |
| Theranexus Société Anonyme | -4.63 Million EUR | 400.686% |
| TME Pharma N.V. | -127 Thousand EUR | 11082.609% |
| Valbiotis SA | 2.66 Million EUR | -422.785% |
| TheraVet SA | -530.79 Thousand EUR | 2727.735% |
| Valerio Therapeutics Société anonyme | 1.26 Million EUR | -1000.861% |
| argenx SE | 925.49 Million EUR | 98.493% |
| BioSenic S.A. | 543 Thousand EUR | -2468.677% |
| Celyad Oncology SA | 33 Thousand EUR | -42166.406% |
| DBV Technologies S.A. | 4.15 Million EUR | -235.319% |
| Galapagos NV | 203.73 Million EUR | 93.154% |
| Genfit S.A. | 28.22 Million EUR | 50.581% |
| GeNeuro SA | -293.8 Thousand EUR | 4847.418% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | -599.494% |
| Innate Pharma S.A. | -4.12 Million EUR | 438.459% |
| Inventiva S.A. | 17.5 Million EUR | 20.298% |
| MaaT Pharma SA | 1.65 Million EUR | -742.774% |
| MedinCell S.A. | 9.28 Million EUR | -50.171% |
| Nanobiotix S.A. | 36.2 Million EUR | 61.478% |
| Onward Medical N.V. | -14.81 Million EUR | 194.128% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -526.31% |
| Oxurion NV | 104 Thousand EUR | -13311.456% |
| Pharming Group N.V. | 220.1 Million EUR | 93.663% |
| Poxel S.A. | 1000.00 EUR | -1394691.4% |
| GenSight Biologics S.A. | 3 Million EUR | -364.93% |
| Transgene SA | -28.4 Million EUR | 149.105% |
| Financière de Tubize SA | -2.02 Million EUR | 787.23% |
| UCB SA | 3.34 Billion EUR | 99.583% |
| Valneva SE | 52.83 Million EUR | 73.602% |
| Vivoryon Therapeutics N.V. | -3.09 Million EUR | 550.66% |